Recent progress in targeted therapy for non-small cell lung cancer
The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people’s health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1125547/full |
| _version_ | 1797900374419439616 |
|---|---|
| author | Yanxia Xiao Pu Liu Jie Wei Xin Zhang Jun Guo Yajun Lin Yajun Lin |
| author_facet | Yanxia Xiao Pu Liu Jie Wei Xin Zhang Jun Guo Yajun Lin Yajun Lin |
| author_sort | Yanxia Xiao |
| collection | DOAJ |
| description | The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people’s health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients has greatly improved. However, in a large number of non-small cell lung cancer cases, the carcinogenic driver is unknown. Identifying genetic alterations is critical for effective individualized therapy in NSCLC. Moreover, targeted drugs are difficult to apply in the clinic. Cancer drug resistance is an unavoidable obstacle limiting the efficacy and application of targeted drugs. This review describes the mechanisms of targeted-drug resistance and newly identified non-small cell lung cancer targets (e.g., KRAS G12C, NGRs, DDRs, CLIP1-LTK, PELP1, STK11/LKB1, NFE2L2/KEAP1, RICTOR, PTEN, RASGRF1, LINE-1, and SphK1). Research into these mechanisms and targets will drive individualized treatment of non-small cell lung cancer to generate better outcomes. |
| first_indexed | 2024-04-10T08:43:54Z |
| format | Article |
| id | doaj.art-9a7ea501d5e04bac95653ceb5ceca5f7 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T08:43:54Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-9a7ea501d5e04bac95653ceb5ceca5f72023-02-22T14:22:11ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-02-011410.3389/fphar.2023.11255471125547Recent progress in targeted therapy for non-small cell lung cancerYanxia Xiao0Pu Liu1Jie Wei2Xin Zhang3Jun Guo4Yajun Lin5Yajun Lin6The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology of National Health Commission, Beijing, ChinaThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology of National Health Commission, Beijing, ChinaThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology of National Health Commission, Beijing, ChinaThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology of National Health Commission, Beijing, ChinaThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology of National Health Commission, Beijing, ChinaThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital, National Center of Gerontology of National Health Commission, Beijing, ChinaPeking University Fifth School of Clinical Medicine, Beijing, ChinaThe high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people’s health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients has greatly improved. However, in a large number of non-small cell lung cancer cases, the carcinogenic driver is unknown. Identifying genetic alterations is critical for effective individualized therapy in NSCLC. Moreover, targeted drugs are difficult to apply in the clinic. Cancer drug resistance is an unavoidable obstacle limiting the efficacy and application of targeted drugs. This review describes the mechanisms of targeted-drug resistance and newly identified non-small cell lung cancer targets (e.g., KRAS G12C, NGRs, DDRs, CLIP1-LTK, PELP1, STK11/LKB1, NFE2L2/KEAP1, RICTOR, PTEN, RASGRF1, LINE-1, and SphK1). Research into these mechanisms and targets will drive individualized treatment of non-small cell lung cancer to generate better outcomes.https://www.frontiersin.org/articles/10.3389/fphar.2023.1125547/fullnon-small cell lung cancerNSCLCtargeted therapydrug resistanceCLIP1-LTK |
| spellingShingle | Yanxia Xiao Pu Liu Jie Wei Xin Zhang Jun Guo Yajun Lin Yajun Lin Recent progress in targeted therapy for non-small cell lung cancer Frontiers in Pharmacology non-small cell lung cancer NSCLC targeted therapy drug resistance CLIP1-LTK |
| title | Recent progress in targeted therapy for non-small cell lung cancer |
| title_full | Recent progress in targeted therapy for non-small cell lung cancer |
| title_fullStr | Recent progress in targeted therapy for non-small cell lung cancer |
| title_full_unstemmed | Recent progress in targeted therapy for non-small cell lung cancer |
| title_short | Recent progress in targeted therapy for non-small cell lung cancer |
| title_sort | recent progress in targeted therapy for non small cell lung cancer |
| topic | non-small cell lung cancer NSCLC targeted therapy drug resistance CLIP1-LTK |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1125547/full |
| work_keys_str_mv | AT yanxiaxiao recentprogressintargetedtherapyfornonsmallcelllungcancer AT puliu recentprogressintargetedtherapyfornonsmallcelllungcancer AT jiewei recentprogressintargetedtherapyfornonsmallcelllungcancer AT xinzhang recentprogressintargetedtherapyfornonsmallcelllungcancer AT junguo recentprogressintargetedtherapyfornonsmallcelllungcancer AT yajunlin recentprogressintargetedtherapyfornonsmallcelllungcancer AT yajunlin recentprogressintargetedtherapyfornonsmallcelllungcancer |